Onco-Actu du 30 mars 2015

Sommaire 2.6 Etiologie - Environnement Glyphosate and Cancer: What does the data say? [Control Freaks] He's Not A Monsanto Lobbyist, And Weed Killer Isn't Safe To Drink [Forbes] 3. Prévention Fit middle-aged men have lower cancer risk [NHS Choices] Coffee probably prevents liver cancer [Cancer Prevention Blog] 3.1 Tabac Smoking ban in outdoor areas the 'next logical step', says Melbourne lord mayor [The Guardian] 3.2 Prévention - Obésité Obesity and cancer – report highlights three things the Government could do [Cancer Research UK] 3.3 Prévention - Vaccins Gardasil 9 offers wider protection against cancers caused by human papillomavirus (HPV) [EMA] 4. Dépistage, diagnostic et pronostic Body scans will detect cancer quicker than invasive biopsies [The Telegraph] 5. Traitements How the Lung-MAP Clinical Trial is Responding to Rapidly Changing Science [The Cancer Letter] If the drugs don't work on the cancer, transform it [New Scientist] 5.2 Pharma Novartis Bets $250M-Plus on Aduro’s Immuno-Oncology Work [Xconomy] Sanofi chairman says acquisitions not 'indispensable' for future [Reuters] 5.3 Traitements - FDA, EMA,... Accelerated assessment fast-tracks Lenvima to benefit patients with thyroid cancer [EMA] Europe postpones decision on Bristol immune system cancer drug [Reuters] Eisai Receives Approval in Japan for Anticancer Agent Lenvima (Lenvatinib Mesylate) as Treatment for Unresectable Thyroid Cancer [Eisai] Further measures to minimise risk of osteonecrosis of the jaw with bisphosphonate medicine [EMA] Eisai gets EMA nod for Lenvima just weeks after FDA approval [FiercePharma] In swansong, FDA chief defends drug approval process [Reuters] 5.6 ESMO Clinical Trial Design in the Era of Targeted Therapies [ESMO] 5.8 ASH Experts Set Strategic Priorities for Lymphoma Research [ASH] 6. Lutte contre les cancers ‘It’s really difficult to be a polymath’ – Sir Paul Nurse on multidisciplinary research [Cancer Research UK ] 6.10 Politiques More States Pass ‘Right to Try’ Laws, But Will These Make a Difference? [Wall Street Journal] 6.11 Patients Chatting With Anne Parker: A Patient's View On How Cancer Care Has Changed Since The 1960s [Forbes] Russian cancer patients are killing themselves because they can’t get pain meds [Quartz] 6.6 Publications Editor quits journal over pay-for-expedited peer-review offer [Science] Ask The Chefs: How Can We Improve the Article Review and Submission Process? [The Scholarly Kitchen] Concern raised over payment for fast-track peer review [Nature News & Comment] 6.8 Communication The conversation about cancer Angelina Jolie will dread [The Telegraph] U.K. government scientists hit with media restrictions [Science] 'CANCER: The Emperor of All Maladies' Preview at AACR Annual Meeting 2014 [AACR] 6.9 Controverses Prostate cancer nurses face extinction at a time when we're most needed [The Guardian] Opinion: Trying to Fool Cancer

Les étoiles de couleur jaune signalent des articles dont la lecture est en priorité suggérée (1*) ou recommandée (3*). 2.6 Etiologie - Environnement Glyphosate and Cancer: What does the data say? [Control Freaks] I’m disappointed that IARC decided to announce the classification about a year before they plan to release the full monograph that details their reason for the decision. He's Not A Monsanto Lobbyist, And Weed Killer Isn't Safe To Drink [Forbes] A journalist from Canal+, the French premium cable station, asks a man identified as a Monsanto lobbyist to drink some RoundUp, or glyphosate, a commonly used weed-killer. 3. Prévention Fit middle-aged men have lower cancer risk [NHS Choices] There was also a counterintuitive finding worth noting. The fittest group were more likely to be diagnosed with prostate cancer than the least fit. This is important, as prostate cancer risk was much higher than lung or colon cancer in the sample. Coffee probably prevents liver cancer [Cancer Prevention Blog] Our new Continuous Update Project (CUP) report shows that drinking coffee is linked to a decreased risk of liver cancer. So what does the research tell us, and what can you do with this information? 3.1 Tabac Smoking ban in outdoor areas the 'next logical step', says Melbourne lord mayor [The Guardian] “I’m not saying don’t smoke, or don’t smoke where people have a drink – it’s a legal product. But we’re the last state that still allows smoking where people are eating outside.” 3.2 Prévention - Obésité Obesity and cancer – report highlights three things the Government could do [Cancer Research UK] We already know that obesity is linked to 9 types of cancer, some more convincingly than others. But this week, new evidence from the World Cancer Research Fund – an organisation with substantial expertise in cancer prevention – has concluded that as well as these types, carrying extra weight can also cause liver cancer. 3.3 Prévention - Vaccins Gardasil 9 offers wider protection against cancers caused by human papillomavirus (HPV) [EMA] The European Medicines Agency (EMA) has recommended Gardasil 9 (human papillomavirus vaccine) for the prevention of diseases caused by nine types of human papillomavirus (HPV). 4. Dépistage, diagnostic et pronostic Body scans will detect cancer quicker than invasive biopsies [The Telegraph] Researchers believe MRI scans could identify cancers non-invasively by detecting telltale sugar molecules. 5. Traitements How the Lung-MAP Clinical Trial is Responding to Rapidly Changing Science [The Cancer Letter] Lung-MAP is unique—a biomarker driven, multi-drug, multi-arm, study design, using a targeted screening approach, with state-of-the-art genomic profiling of neoplastic cells to match patients with sub-studies testing investigational new drugs and immunotherapies, based on their unique tumor profiles. If the drugs don't work on the cancer, transform it [New Scientist] "Maybe we can shift the tumour in the direction of the therapy rather than developing the therapy in the direction of the tumour," says Rob Ramsay from the Peter MacCallum Cancer Centre in Melbourne, Australia. 5.2 Pharma Novartis Bets $250M-Plus on Aduro’s Immuno-Oncology Work [Xconomy] The big upfront haul is particularly notable given that Aduro hasn’t yet tested a STING drug in clinical trials. So far, Aduro has only demonstrated that an experimental STING activator compound it’s developing called ADU-S100 can curb tumor growth in animals. Sanofi chairman says acquisitions not 'indispensable' for future [Reuters] "We looked at potential deals but found the asking prices to be too high for the businesses," said Sanofi Chairman Serge Weinberg. 5.3 Traitements - FDA, EMA,... Accelerated assessment fast-tracks Lenvima to benefit patients with thyroid cancer [EMA] Lenvima offers treatment option for patients who no longer respond to standard therapy Europe postpones decision on Bristol immune system cancer drug [Reuters] Such postponements happen fairly often when questions arise and officials feel they need more time to evaluate a medicine. The nivolumab application could be considered again either in April or at a later date, the spokeswoman added. Eisai Receives Approval in Japan for Anticancer Agent Lenvima (Lenvatinib Mesylate) as Treatment for Unresectable Thyroid Cancer [Eisai] Lenvima is an orally administered molecular targeted agent that selectively inhibits the activities of several different molecules including VEGFR, FGFR, RET, KIT and PDGFR. Further measures to minimise risk of osteonecrosis of the jaw with bisphosphonate medicine [EMA] Measures for other intravenous bisphosphonates and denosumab to be considered in upcoming reviews. Eisai gets EMA nod for Lenvima just weeks after FDA approval [FiercePharma] Lenvima will compete with Bayer's cancer-fighter Nexavar, which won approval in 2013 for treating thyroid cancer, but Eisai is also hoping to win approval for the drug for treating other cancers such as liver, kidney, lung and endometrial cancers. In swansong, FDA chief defends drug approval process [Reuters] "In the race for the newest treatment we must remember the point that innovation doesn't matter if the product doesn't work," she said. 5.6 ESMO Clinical Trial Design in the Era of Targeted Therapies [ESMO] The two-day course addresses the fundamental aspects of clinical trials, such as the selection of appropriate endpoints, statistics for clinicians, and the use of biomarkers in clinical trials of targeted treatment modalities. 5.8 ASH Experts Set Strategic Priorities for Lymphoma Research [ASH] The report is meant to inform future research directions as well as funding decisions by strategic partners that could include government agencies and the private sector. 6. Lutte contre les cancers ‘It’s really difficult to be a polymath’ – Sir Paul Nurse on multidisciplinary research [Cancer Research UK ] In his capacity as Director of the Francis Crick Institute – which opens its doors next month – he’s spearheading one of the UK’s most exciting ventures into modern multidisciplinary science. 6.10 Politiques More States Pass ‘Right to Try’ Laws, But Will These Make a Difference? [Wall Street Journal] The move reflects rising frustration with an FDA program called expanded access, in which people who are seriously ill can obtain a drug under development, even though they aren’t enrolled in a clinical trial. 6.11 Patients Chatting With Anne Parker: A Patient's View On How Cancer Care Has Changed Since The 1960s [Forbes] At a time when few physicians thought that there was a genetic cause of breast cancer, Parker sought information and pushed her doctors for answers. Her perspective on oncology – as a family member, patient and advocate – spans over 50 years. Russian cancer patients are killing themselves because they can’t get pain meds [Quartz] “This poor woman was so afraid of the pain coming back,” the woman whispered to Polina, “that she begged her relatives to carry her outside in nothing but her underwear and lay her on the snow. ‘Lay me down and wait. And then bring me back inside. I’ll get pneumonia and die.’” 6.6 Publications Editor quits journal over pay-for-expedited peer-review offer [Science] The flap shines a light on a fledgling industry where several companies are now making millions of dollars by privatizing peer review. Ask The Chefs: How Can We Improve the Article Review and Submission Process? [The Scholarly Kitchen] Improving the system has to have a benefit for the publisher or it won’t happen. Concern raised over payment for fast-track peer review [Nature News & Comment] Scientist resigns from NPG’s Scientific Reports journal over pilot project. 6.8 Communication The conversation about cancer Angelina Jolie will dread [The Telegraph] ‘‘Angelina must be looking at her biological children - Shiloh, eight, and six-year-old twins Knox and Vivienne - and thinking, ‘when do I have The Conversation with you?’ The conversation in which she must persuade them to be tested when they are old enough to understand. U.K. government scientists hit with media restrictions [Science] Advocates for science communication in the United Kingdom have expressed “deep concern” about a change to the Civil Service Code for public workers, including researchers at government agencies. The three-sentence addition, put into place on 16 March, requires that all contact with media be approved in advance by the minister in charge of the relevant agency. 'CANCER: The Emperor of All Maladies' Preview at AACR Annual Meeting 2014 [AACR] The American Association for Cancer Research (AACR), the world's oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer, is proud to be an outreach partner for "CANCER: The Emperor of All Maladies," a film documentary presented by Ken Burns. 6.9 Controverses Prostate cancer nurses face extinction at a time when we're most needed [The Guardian] There’s no denying that I love my job. But in recent years it has become plagued by increasing, unmanageable workloads and huge administrative demands, which often makes me question why I am still doing it. Opinion: Trying to Fool Cancer We shouldn’t delude ourselves, or our patients, in thinking that standard chemotherapy is a thing of the past. Or that a few more months of life, which is what many targeted drugs have been able to deliver on average, is a panacea in cancer care.